Safety and Tolerability of Autologous Adipose-derived Mesenchymal Stem Cells Therapy in Adults With Atrophic Scars

A phase 1 clinical trial to evaluate dose-limiting toxicity by administering a singe dose of TRTP-101 to each of the four sites of atrophic scar.

Inclusion criteria

• Male or Female aged greater than 19 years
• Four or more atrophic scars in the joints, genitals, perineum, and face except for the lips, eyes and nose

Exclusion criteria

• History of cell therapy
• Treatment of Dermal resurfacing, Chemical/Mechanical Peel and Skin Photorejuvenation
• Treatment of Hyaluronic acid/collagen skin filler, non-permanent soft tissue filler and fat grafting
• Positive for virus infection
• Use of Anticoagulant therapy or NSAIDs
• Thrombocytopenia or other coagulation disorder
• History of keloid scars
• Infectious disease or other dermatitis in the area of the atrophic scar
• Use of Immunosuppressant, immunomodulating drug, anticancer drug or radiation therapy
• Use of systemic steroid medication
• History of hypersensitivity or severe allergic reactions (e.g., anaphylaxis, Guillain-Barre syndrome, etc.)
• Use of retinoid medications